Pacific Biosciences (PACB) is scheduled to report Q1 earnings on May 7, 2026. Analysts estimate EPS of $-0.15 and quarterly revenue of $40.39M.

In the most recent quarter (Q4), Pacific Biosciences reported EPS of $-0.12, beating estimates of $-0.16 by 0.25%. Revenue came in at $44.65M, exceeding the estimate of $41.83M by 0.07%.

Pacific Biosciences has beaten EPS estimates in 8 consecutive quarters.

Over the last 4 quarters, Pacific Biosciences has averaged an EPS surprise of 0.22% and a revenue surprise of 0.05%.